Related Experiment Videos
[Von Willebrand factor in coronary disease]
P Soskin1, M L Wiesel, J M Mossard
1Service de cardiologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|January 1, 1994
Summary
Elevated levels of von Willebrand factor (VWF) are observed in patients with coronary artery disease and acute myocardial infarction. VWF is a key factor in thrombosis and a sensitive, though not specific, marker for myocardial infarction.
Area of Science:
- Cardiovascular Biology
- Hematology
- Thrombosis Research
Context:
- Coronary artery disease (CAD) involves complex interactions between endothelial injury, thrombosis, and hemostasis.
- Acute coronary syndromes and interventions like coronary angioplasty are significantly influenced by thrombus formation.
- The von Willebrand factor (VWF) plays a critical role in primary hemostasis and platelet aggregation.
Purpose:
- To investigate the role and significance of von Willebrand factor (VWF) in the context of coronary artery disease.
- To analyze VWF concentration changes in patients experiencing acute myocardial infarction.
- To assess VWF as a diagnostic marker and its correlation with disease severity and inflammatory markers.
Summary:
- Von Willebrand factor (VWF), synthesized by endothelial cells, promotes platelet adhesion and aggregation, crucial for thrombus formation.
- Experimental models demonstrate VWF's essential role in forming occlusive thrombi.
- Elevated VWF levels are consistently found in patients with acute myocardial infarction, peaking around day 5 and remaining high at day 15.
Impact:
- VWF is identified as a sensitive, albeit non-specific, late diagnostic marker for myocardial infarction.
- Increased VWF concentrations correlate with infarct size, inflammatory response, and the prothrombotic state in CAD patients.
- Understanding VWF dynamics offers insights into the pathophysiology of thrombotic events in cardiovascular disease.